Medexus Pharmaceuticals Inc has shown notable price action this week, reflecting investor interest following recent corporate developments.
Medexus Pharmaceuticals Inc (MDP.TO) experienced a positive week, with shares rising by 9.44%. The stock closed at C$5.34, marking a 1.49% increase on the last trading day. This performance aligns with the company's recent announcements and ongoing developments in its product offerings.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$157.13M
52W high
$5.50
52W low
$2.51
1W change
-1.57%
Beta
1.83
Analyst Price Targets
Based on analyst covering MDP · as of Sep 17, 2026
Wall Street analysts forecast MDP stock price to rise 45.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+45.0% Upside
Current Price
C$5.00
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
30.8%
Annualized
90-Day Vol
38.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.34 | C$4.80 – C$5.94 |
| 60 trading days | C$5.67 | C$4.87 – C$6.59 |
| 90 trading days | C$6.01 | C$5.00 – C$7.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may find reassurance in Medexus's strong fiscal performance and strategic partnerships, particularly as the company continues to expand its portfolio with new therapies.
76% YTD Gain for Medexus Pharmaceuticals
Medexus Pharmaceuticals has delivered a remarkable 76.38% increase year-to-date, reflecting strong investor confidence and operational performance.
Bull case
Medexus's fiscal year 2026 results highlight its operational momentum, particularly with the success of GRAFAPEX (treosulfan) for Injection. The recent licensing agreement for UM171 Cell Therapy could further boost the company's growth prospects.
Bear case
Despite these positive developments, Medexus's profit margin remains negative, and the company has not yet achieved profitability. This situation may raise concerns for risk-averse investors.
Recent Price Action
This week, Medexus Pharmaceuticals Inc (MDP.TO) saw its stock rise by 9.44%, closing at C$5.34. The share price has gained 1.49% in the last trading session, reflecting positive sentiment among investors following the company's recent announcements.
Company News and Developments
Advertisement
Medexus recently announced its fiscal year 2026 results, showcasing strong performance driven by GRAFAPEX (treosulfan) for Injection. The company also entered into a licensing and supply agreement for UM171 Cell Therapy in Canada, signaling its commitment to expanding its therapeutic offerings. Moreover, Medexus scheduled a conference call to discuss its fourth fiscal quarter and fiscal year 2026 results, indicating transparency and engagement with investors.
Technical Picture
Medexus Pharmaceuticals currently trades above its 50-day moving average of C$4.69 by 13.8% and its 200-day moving average of C$3.54 by 50.8%. The stock has a 52-week range of C$2.51 to C$5.50, with the current price reflecting 95% of this range. The beta of 1.84 suggests higher volatility compared to the market, while the trading volume of 33,492 shares is approximately 1.15 times the 20-day average volume of 44,893 shares.
Insider Activity
There is no recent insider activity reported for Medexus Pharmaceuticals, which may indicate stable management and shareholder confidence.
Price Action Summary
Medexus Pharmaceuticals Inc closed at C$5.34, reflecting a 1.49% increase on the last trading day. The stock's year-to-date performance shows a remarkable gain of 76.38%, highlighting strong investor interest and confidence in the company's strategic direction.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
